Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

  1. Kim, Y.H.
  2. Prince, H.M.
  3. Whittaker, S.
  4. Horwitz, S.M.
  5. Duvic, M.
  6. Bechter, O.
  7. Sanches, J.A.
  8. Stadler, R.
  9. Scarisbrick, J.
  10. Quaglino, P.
  11. Zinzani, P.L.
  12. Wolter, P.
  13. Eradat, H.
  14. Pinter-Brown, L.C.
  15. Ortiz-Romero, P.L.
  16. Akilov, O.E.
  17. Trotman, J.
  18. Taylor, K.
  19. Weichenthal, M.
  20. Walewski, J.
  21. Fisher, D.
  22. McNeeley, M.
  23. Gru, A.A.
  24. Brown, L.
  25. Palanca-Wessels, M.C.
  26. Lisano, J.
  27. Onsum, M.
  28. Bunn, V.
  29. Little, M.
  30. Trepicchio, W.L.
  31. Dummer, R.
  32. Erakutsi egile guztiak +
Aldizkaria:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Argitalpen urtea: 2021

Alea: 148

Orrialdeak: 411-421

Mota: Artikulua

DOI: 10.1016/J.EJCA.2021.01.054 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus